News | Congenital Heart | May 02, 2022

Scientists Implicate Non-cardiac Genes in Congenital Heart Disease

Researchers conducted experiments to show how a non-cardiac protein subunit interacts with three cardiac genes known to be mutated in patients with congenital heart disease.

Heart cells

Cross section through an embryonic mouse heart showing misexpression of smooth muscle myosin heavy chain (MYH11) in cardiomyocytes (green). Cell nuclei shown in blue. Credit: Frank Conlon Lab (UNC-Chapel Hill)


May 2, 2022 – Inside embryonic cells, specific proteins control the rate at which genetic information is transcribed from DNA to messenger RNA – a crucial regulatory step before proteins are created. Then, organs develop and hopefully function properly. Those specific “regulatory” proteins are called transcription factors, and they do their thing by binding to specific DNA sequences at just the right time.

Scientists have known that mutations to three cardiac transcription factors – GATA4, NKX2-5 and TBX5 – lead to a range of congenital heart disease states. Researchers have thought that an inability of these mutated genes to “turn on” cardiac genes is what led to heart disease.

Now, the lab of Frank Conlon, PhD, professor of biology and genetics at the University of North Carolina at Chapel Hill, discovered there’s more to the story. It involves non-cardiac genes, as well as answering a question researchers have struggled with for years.

Aside from the aforementioned transcription factors, past research showed that a protein complex subunit called CHD4 seems to play a major role in congenital heart disease. Deleting it causes embryonic death in animal models. Mutations to it cause major problems with proteins involved in skeletal and muscle development.

Turns out, CHD4 is essential for numerous developmental events, such as ensuring proper timing of the switch from stem cell lineages to differentiated cell types – that is, the moment when stem cells turn into, say, heart cells or leg muscle cells. CDH4 also is essential for maintaining cell differentiation – keeping heart cells healthy heart cells. And CDH4 is a player in activating cellular processes to deal with DNA damage.

Yet, CHD4 cannot bind DNA. It needs to be brought to a specific location, or genetic loci, of a cardiac gene to do its things. So, scientists could not answer the key question of how CHD4 played its role in cardiac disease.

Conlon’s lab, in collaboration with colleagues at UNC-Chapel Hill, Princeton, and Boston Children’s Hospital, shows that GATA4, NKX2-5 and TBX5 interact with CHD4 inside the embryonic heart, recruiting it for action, and that’s how CHD4 plays its role in heart health and disease.

These findings, published in the journal Genes & Development, imply that heart disease states are not only due to loss of cardiac gene expression, but that these genes’ recruitment of CHD4 can lead to a misexpression of non-cardiac genes, leading in the end to faulty heart development.

To put this implication to the test, Conlon and his collaborators removed the binding site for Nkx2-5 in the skeletal muscle gene Acta1 in mice and, independently, the GATA4 binding site in the smooth muscle gene Myh11.

“In both instances, the mutation led to the inappropriate expression of the non-cardiac genes in the heart in a dominant manner,” said Conlon, a member of the UNC McAllister Heart Institute. “This provides a mechanism for the prevalence of congenital heart disease in humans with just one mutated copy of Nkx2-5, Gata4 or Tbx5.”

Related Content

News | Heart Failure

August 8, 2022 — A major risk factor for diabetes, insulin resistance occurs when the cells of the body do not respond ...

Home August 08, 2022
Home
News | Heart Failure

August 5, 2022 — For people with coronary heart disease, beta-blockers can improve survival and quality of life, while ...

Home August 05, 2022
Home
News | Heart Failure

July 27, 2022 — The world’s first HIV-positive to HIV-positive heart transplant has been successfully performed at ...

Home July 27, 2022
Home
News | Heart Failure

July 27, 2022 — Researchers from RCSI University of Medicine and Health Sciences have developed a new lab-based model of ...

Home July 27, 2022
Home
News | Heart Failure

July 20, 2022 — Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and ...

Home July 20, 2022
Home
News | Heart Failure

July 15, 2022 — The American Heart Association, the leading voluntary organization devoted to longer, healthier lives ...

Home July 15, 2022
Home
News | Heart Failure

July 13, 2022 — Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today ...

Home July 13, 2022
Home
News | Heart Failure

July 12, 2022 — Pesticides and heavy metals in soil may have detrimental effects on the cardiovascular system, according ...

Home July 12, 2022
Home
News | Heart Failure

July 7, 2022 — Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver ...

Home July 07, 2022
Home
News | Heart Failure

June 29, 2022 — A spiral wave of electrical activity in the heart can cause catastrophic consequences. One spiral wave ...

Home June 29, 2022
Home
Subscribe Now